You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Dow
Merck
Colorcon

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for sulfur hexafluoride lipid-type a microspheres

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03040323 Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses Recruiting Indiana University Phase 4 2016-12-22 The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
NCT03300401 Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization Not yet recruiting National Cancer Institute (NCI) N/A 2017-10-09 This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.
NCT03300401 Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization Not yet recruiting University of Southern California N/A 2017-10-09 This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.
NCT03407001 Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis Recruiting National Cancer Institute (NCI) Early Phase 1 2018-01-12 The goal of this clinical research study is to find out if ultrasound scans using a contrast agent called Lumason (sulfur hexafluoride lipid-type A microspheres) can help doctors more easily find liver lesions (including hepatocellular carcinoma [HCC]), compared to ultrasounds without contrast agent. Contrast agents are drugs that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Researchers will also compare the effectiveness of liver ultrasounds using Lumason versus standard MRI imaging, in patients with cirrhosis of the liver. This is an investigational study. Ultrasound and MRI scans on this study are performed using FDA-approved and commercially available methods. Up to 150 patients will be enrolled on this research study. All will take part at MD Anderson.
NCT03407001 Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis Recruiting M.D. Anderson Cancer Center Early Phase 1 2018-01-12 The goal of this clinical research study is to find out if ultrasound scans using a contrast agent called Lumason (sulfur hexafluoride lipid-type A microspheres) can help doctors more easily find liver lesions (including hepatocellular carcinoma [HCC]), compared to ultrasounds without contrast agent. Contrast agents are drugs that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Researchers will also compare the effectiveness of liver ultrasounds using Lumason versus standard MRI imaging, in patients with cirrhosis of the liver. This is an investigational study. Ultrasound and MRI scans on this study are performed using FDA-approved and commercially available methods. Up to 150 patients will be enrolled on this research study. All will take part at MD Anderson.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for sulfur hexafluoride lipid-type a microspheres

Condition Name

Condition Name for sulfur hexafluoride lipid-type a microspheres
Intervention Trials
Hepatocellular Carcinoma 2
Liver Biopsy 1
Diseases of Liver 1
Acute Appendicitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for sulfur hexafluoride lipid-type a microspheres
Intervention Trials
Carcinoma, Hepatocellular 2
Carcinoma 2
Appendicitis 1
Liver Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for sulfur hexafluoride lipid-type a microspheres

Trials by Country

Trials by Country for sulfur hexafluoride lipid-type a microspheres
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for sulfur hexafluoride lipid-type a microspheres
Location Trials
Missouri 1
Texas 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for sulfur hexafluoride lipid-type a microspheres

Clinical Trial Phase

Clinical Trial Phase for sulfur hexafluoride lipid-type a microspheres
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
N/A 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for sulfur hexafluoride lipid-type a microspheres
Clinical Trial Phase Trials
Recruiting 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for sulfur hexafluoride lipid-type a microspheres

Sponsor Name

Sponsor Name for sulfur hexafluoride lipid-type a microspheres
Sponsor Trials
National Cancer Institute (NCI) 2
Children's Mercy Hospital Kansas City 1
M.D. Anderson Cancer Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for sulfur hexafluoride lipid-type a microspheres
Sponsor Trials
Other 4
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
Dow
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.